Skip to main content
S&P 5007,666.45+0.19%DOW50,926.56+0.04%NASDAQ26,871.60+0.04%BTC$84,785.00+1.59%ETH$2,703.77+0.83%GOLD$4,211.30+0.21%OIL$92.870.00%
Smart Investors Daily
SID Premium
ZB

NASDAQ · ZBIO

Zenas BioPharma, Inc.

Healthcare · Biotechnology

$26.97

Up+$0.97 (+3.60%)

Updated Oct 2, 2026, 12:13 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69B
P/E ratio
-9.52
Dividend yield
0.00%
52-week range
$16.41 – $34.05
Volume
623.27K
Avg. volume
419.1K

Price performance · ZBIO

ZBIO price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Sep 30, 2026

ZBIO closed at $26.97 after 19 trading sessions, down 18.07% for the selected period.

Last close
$26.97
Period change
-18.07%
Period low
$26.76
Period high
$33.05
Daily close
View OHLC price history
ZBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 30, 2026$26.99$28.38$26.54$26.97623.27K
Sep 29, 2026$27.30$27.615$26.18$26.76440.64K
Sep 28, 2026$27.07$28.23$26.455$27.55615.35K
Sep 25, 2026$27.44$28.50$25.90$26.95747.86K
Sep 24, 2026$29.51$30.12$25.70$27.50963.04K
Sep 23, 2026$33.09$33.09$29.5301$29.63525.14K
Sep 22, 2026$32.55$33.8444$32.15$33.05452.81K
Sep 21, 2026$31.62$33.19$31.00$32.55414.5K
Sep 18, 2026$32.04$32.04$31.25$31.502.52M
Sep 17, 2026$32.78$33.48$31.55$31.97527.84K
Sep 16, 2026$31.89$33.23$31.585$32.32746.41K
Sep 15, 2026$32.06$32.06$30.27$31.93715.98K
Sep 14, 2026$31.00$32.00$30.66$31.91634.64K
Sep 11, 2026$31.48$32.315$31.12$31.12421.7K
Sep 10, 2026$31.88$31.89$30.73$31.10646.94K
Sep 9, 2026$33.02$33.525$32.085$32.29385.38K
Sep 8, 2026$32.65$33.84$32.305$33.05441.2K
Sep 4, 2026$32.66$33.29$32.381$32.88452.69K
Sep 3, 2026$33.42$33.66$32.365$32.92515.12K

Latest ZBIO news

The latest Smart Investors Daily articles mentioning ZBIO.

Stock researchCompany · Overview

ZBIO research

Overview

Company profile and research snapshot.

Company profile

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.33
Implied upside
—
Analysts
—
ZBIO recent ratings
DateFirmRatingTarget
Sep 30, 2026WedbushOutperform—
Sep 30, 2026HC Wainwright & Co.Buy—
Sep 30, 2026CitigroupBuy—
Aug 14, 2026WedbushOutperform—
Aug 14, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 20, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,

Yahoo · Feb 19, 2026

Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimism about potential monetary easing and caution regarding economic growth and valuations. Early gains were driven by strong AI-related earnings […]

Yahoo · Feb 18, 2026

Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial Success - And What's Next

Zenas BioPharma recently reported that its lead candidate obexelimab met the primary endpoint in the Phase 2 MoonStone trial in relapsing multiple sclerosis, with a highly statistically significant reduction in new gadolinium-enhancing T1 lesions and a safety profile consistent with prior studies. The data, presented as a late-breaking oral session at the ACTRIMS Forum 2026 and supported by 24-week durability results, highlight obexelimab’s potential to curb inflammatory brain activity while...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By